Heparin-induced thrombocytopenia.
Heparin is one of the most frequently prescribed medications in the United States with more than 1 trillion units being used each year. However, some patients who receive heparin may have development of a rare but severe complication called heparin-induced thrombocytopenia, which is associated with significant morbidity and mortality rates. This syndrome is a clinical event in which the use of heparin results in thrombocytopenia, venous or arterial thrombosis, and, less commonly, bleeding. The exact mechanism of heparin-induced thrombocytopenia is not clearly understood, but an immune-mediated response to heparin resulting in platelet consumption is the most widely accepted theory. The main treatment is discontinuation of heparin therapy; however, alternative treatments are discussed. The critical role nurses play in the early detection and prevention of the complications of heparin-induced thrombocytopenia is addressed. Assessment of all patients receiving any form of heparin therapy is emphasized.
Fahey
V A
VA
D000925:Anticoagulants / Q000009:adverse effects*; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced / Q000175:diagnosis / Q000628:therapy
D000925:Anticoagulants; D006493:Heparin